Friday, March 2, 2012
Sanofi is looking for more ‘real-world’ insight into its drug development and product lifecycle strategies by teaming up with pharmacy benefit manager Medco Health Solutions to help deliver value propositions that can withstand tough scrutiny from regulators and payers, reports PharmaTimes.
UCB published results from a post hoc analysis of the RAPID 2 study in the Annals of Rheumatic Diseases, which showed Cimzia, the only approved PEGylated anti-TNF, plus methotrexate (MTX) provided rapid relief from a broad range of symptoms associated with the burden of moderate to severe active rheumatoid arthritis (RA). Adult patients treated with Cimzia that achieved early responses were found to have an increased chance of achieving longer-term outcomes.
United BioSource (UBC), a pharmaceutical services company that specializes in post-approval drug research, has agreed to be bought by Medco Health Solutions for $730 million in an all-cash deal as part of the pharmacy-benefit management (PBM) company’s strategy to expand beyond its core business and promote medical treatment based on research evidence.
United BioSource Corporation (UBC), a global scientific and medical affairs organization based in Bethesda, Md., has secured a new line of credit that provides the company with up to $150 million in additional financing for acquisitions and other significant growth investments. Wells Fargo, PNC Bank, Capital One and JPMorgan Chase participated in financing the new credit facility.